Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
2.

Baseline characteristics and enrichment results from the SONAR trial.

Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2018 Aug;20(8):1829-1835. doi: 10.1111/dom.13315. Epub 2018 May 1.

3.

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.

Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2018 Jun;20(6):1369-1376. doi: 10.1111/dom.13245. Epub 2018 Mar 9.

4.

Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.

Kröpelin TF, de Zeeuw D, Andress DL, Bijlsma MJ, Persson F, Parving HH, Heerspink HJ.

Clin J Am Soc Nephrol. 2015 Mar 6;10(3):410-6. doi: 10.2215/CJN.07780814. Epub 2015 Jan 7.

5.

Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.

Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D.

Nephrol Dial Transplant. 2013 Sep;28(9):2260-8. doi: 10.1093/ndt/gft227. Epub 2013 Jun 19.

6.

Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).

Andress DL, Coll B, Pritchett Y, Brennan J, Molitch M, Kohan DE.

Life Sci. 2012 Oct 15;91(13-14):739-42. doi: 10.1016/j.lfs.2012.01.011. Epub 2012 Feb 2.

7.

Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.

Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S.

Am J Kidney Dis. 2012 Jan;59(1):58-66. doi: 10.1053/j.ajkd.2011.06.027. Epub 2011 Aug 31.

PMID:
21885174
8.

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.

Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL.

J Am Soc Nephrol. 2011 Apr;22(4):763-72. doi: 10.1681/ASN.2010080869. Epub 2011 Mar 3.

9.

Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions.

Isakova T, Gutiérrez OM, Patel NM, Andress DL, Wolf M, Levin A.

J Ren Nutr. 2011 Jul;21(4):295-302. doi: 10.1053/j.jrn.2010.07.002. Epub 2010 Sep 3.

PMID:
20817560
10.

Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

Schumock GT, Walton SM, Lee TA, Marx SE, Audhya P, Andress DL.

Nephron Clin Pract. 2011;117(2):c151-9. doi: 10.1159/000319781. Epub 2010 Aug 10.

PMID:
20699620
11.

Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model.

Nuijten M, Andress DL, Marx SE, Curry AS, Sterz R.

Clin Drug Investig. 2010;30(8):545-57. doi: 10.2165/11536310-000000000-00000.

PMID:
20586517
12.

Vitamin D deficiency and anemia in early chronic kidney disease.

Patel NM, Gutiérrez OM, Andress DL, Coyne DW, Levin A, Wolf M.

Kidney Int. 2010 Apr;77(8):715-20. doi: 10.1038/ki.2009.551. Epub 2010 Feb 3.

13.

Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients.

Lund RJ, Andress DL, Amdahl M, Williams LA, Heaney RP.

Am J Nephrol. 2010;31(2):165-70. doi: 10.1159/000266204. Epub 2009 Dec 11.

PMID:
20016142
14.

Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients.

Schumock GT, Andress DL, Marx SE, Sterz R, Joyce AT, Kalantar-Zadeh K.

Nephron Clin Pract. 2009;113(1):c54-61. doi: 10.1159/000228076. Epub 2009 Jul 10.

15.

The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.

Lambers Heerspink HJ, Agarwal R, Coyne DW, Parving HH, Ritz E, Remuzzi G, Audhya P, Amdahl MJ, Andress DL, de Zeeuw D.

Am J Nephrol. 2009;30(3):280-6. doi: 10.1159/000225903. Epub 2009 Jun 15.

PMID:
19521070
16.

Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.

Nuijten M, Andress DL, Marx SE, Sterz R.

Curr Med Res Opin. 2009 May;25(5):1221-34. doi: 10.1185/03007990902844097 .

PMID:
19335321
17.

Adynamic bone in patients with chronic kidney disease.

Andress DL.

Kidney Int. 2008 Jun;73(12):1345-54. doi: 10.1038/ki.2008.60. Epub 2008 Mar 12. Review.

18.

Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease.

Gutiérrez OM, Isakova T, Andress DL, Levin A, Wolf M.

Kidney Int. 2008 Apr;73(8):956-62. doi: 10.1038/ki.2008.4. Epub 2008 Feb 6.

19.

Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.

Andress DL, Coyne DW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM.

Endocr Pract. 2008 Jan-Feb;14(1):18-27. Review.

PMID:
18238737
20.

Bone and mineral guidelines for patients with chronic kidney disease: a call for revision.

Andress DL.

Clin J Am Soc Nephrol. 2008 Jan;3(1):179-83. Epub 2007 Dec 5. Review.

21.

Superiority of the Modification of Diet in Renal Disease equation over the Cockcroft-Gault equation in screening for impaired kidney function in Japanese Americans.

Gerchman F, Tong J, Utzschneider KM, Hull RL, Zraika S, Udayasankar J, McNeely MJ, Andress DL, Leonetti DL, Boyko EJ, Fujimoto WY, Kahn SE.

Diabetes Res Clin Pract. 2007 Aug;77(2):320-6. Epub 2006 Dec 4.

22.

Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.

Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL.

Kidney Int. 2007 Jan;71(1):31-8. Epub 2006 Nov 8. Erratum in: Kidney Int. 2009 Jun;75(11):1237. Erratum in: Kidney Int. 2009 Jun 1;75(11):1237.

23.

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM.

Am J Kidney Dis. 2006 Feb;47(2):263-76.

PMID:
16431255
24.
25.

Vitamin D treatment in chronic kidney disease.

Andress DL.

Semin Dial. 2005 Jul-Aug;18(4):315-21. Review.

PMID:
16076355
26.

Serum phosphate levels and mortality risk among people with chronic kidney disease.

Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL.

J Am Soc Nephrol. 2005 Feb;16(2):520-8. Epub 2004 Dec 22.

27.

Survival following parathyroidectomy among United States dialysis patients.

Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C.

Kidney Int. 2004 Nov;66(5):2010-6.

28.

Vitamin D analogs in uremia: integrating medical and nutritional issues.

Jernigan P, Andress DL.

Adv Ren Replace Ther. 2003 Jul;10(3):241-7. Review.

PMID:
14708080
29.

IGF-1-induced lipid accumulation impairs mesangial cell migration and contractile function.

Berfield AK, Andress DL, Abrass CK.

Kidney Int. 2002 Oct;62(4):1229-37.

30.

Antiepileptic drug-induced bone loss in young male patients who have seizures.

Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, Spain W.

Arch Neurol. 2002 May;59(5):781-6.

PMID:
12020260
31.

Lower target calcium levels in dialysis patients.

Andress DL.

Semin Dial. 2002 Jan-Feb;15(1):74. No abstract available.

PMID:
11874601
32.

Cytokine accumulation in osteitis fibrosa of renal osteodystrophy.

Duarte ME, Carvalho EF, Cruz EA, Lucena SB, Andress DL.

Braz J Med Biol Res. 2002 Jan;35(1):25-9.

33.

Intravenous versus oral vitamin d therapy in dialysis patients: what is the question?

Andress DL.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S41-4. Review.

PMID:
11689386
34.

Intact IGF-binding protein-4 and -5 and their respective fragments isolated from chronic renal failure serum differentially modulate IGF-I actions in cultured growth plate chondrocytes.

Kiepe D, Andress DL, Mohan S, Ständker L, Ulinski T, Himmele R, Mehls O, Tönshoff B.

J Am Soc Nephrol. 2001 Nov;12(11):2400-10.

35.
36.

Vitamin D analogs in uremia: integrating medical and nutritional issues.

Jernigan P, Andress DL.

J Ren Nutr. 2001 Jan;11(1):3-8. Review.

PMID:
11172447
37.

IGFBP-5(201-218) stimulates Cdc42GAP aggregation and filopodia formationin migrating mesangial cells.

Berfield AK, Andress DL, Abrass CK.

Kidney Int. 2000 May;57(5):1991-2003.

38.

Insulin-like growth factor binding protein-5 proteolytic activity in ovine articular chondrocyte culture.

Sunic D, McNeil JD, Andress DL, Belford DA.

Biochim Biophys Acta. 1998 Nov 27;1425(3):567-76.

PMID:
9838220
39.

Regulation of insulin-like growth factor-binding protein-5 by insulin-like growth factor I and interleukin-1alpha in ovine articular chondrocytes.

Sunic D, McNeil JD, Rayner TE, Andress DL, Belford DA.

Endocrinology. 1998 May;139(5):2356-62.

PMID:
9564845
40.

Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor.

Andress DL.

Am J Physiol. 1998 Apr;274(4):E744-50. doi: 10.1152/ajpendo.1998.274.4.E744.

PMID:
9575837
41.
42.

Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration.

Abrass CK, Berfield AK, Andress DL.

Am J Physiol. 1997 Dec;273(6):F899-906. doi: 10.1152/ajprenal.1997.273.6.F899.

PMID:
9435678
43.

Insulin-like growth factor (IGF)-binding protein-5-(201-218) region regulates hydroxyapatite and IGF-I binding.

Campbell PG, Andress DL.

Am J Physiol. 1997 Nov;273(5):E1005-13. doi: 10.1152/ajpendo.1997.273.5.E1005.

PMID:
9374688
44.

Plasmin degradation of insulin-like growth factor-binding protein-5 (IGFBP-5): regulation by IGFBP-5-(201-218).

Campbell PG, Andress DL.

Am J Physiol. 1997 Nov;273(5):E996-1004. doi: 10.1152/ajpendo.1997.273.5.E996.

PMID:
9374687
45.

Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure.

Kates DM, Sherrard DJ, Andress DL.

Am J Kidney Dis. 1997 Dec;30(6):809-13.

PMID:
9398125
46.

Growth hormone receptor activity is stimulated by insulin-like growth factor binding protein 5 in rat osteosarcoma cells.

Slootweg MC, Ohlsson C, van Elk EJ, Netelenbos JC, Andress DL.

Growth Regul. 1996 Dec;6(4):238-46.

PMID:
8971553
47.

Magnetic resonance imaging of dialysis-related amyloidosis of the shoulder and hip.

Escobedo EM, Hunter JC, Zink-Brody GC, Andress DL.

Skeletal Radiol. 1996 Jan;25(1):41-8.

PMID:
8717118
49.

IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain.

Booth BA, Boes M, Andress DL, Dake BL, Kiefer MC, Maack C, Linhardt RJ, Bar K, Caldwell EE, Weiler J, et al.

Growth Regul. 1995 Mar;5(1):1-17.

PMID:
7538367
50.

IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3.

Drivdahl RH, Loop SM, Andress DL, Ostenson RC.

Prostate. 1995 Feb;26(2):72-9.

PMID:
7531847

Supplemental Content

Loading ...
Support Center